Unknown

Dataset Information

0

Modulation of tumor microenvironment by targeting histone acetylation in bladder cancer.


ABSTRACT: Alterations in the epigenetic machinery in both tumor and immune cells contribute to bladder cancer (BC) development, constituting a promising target as an alternative therapeutic option. Here, we have explored the effects of a novel histone deacetylase (HDAC) inhibitor CM-1758, alone or in combination with immune checkpoint inhibitors (ICI) in BC. We determined the antitumor effects of CM-1758 in various BC cell lines together with the induction of broad transcriptional changes, with focus on the epigenetic regulation of PD-L1. Using an immunocompetent syngeneic mouse model of metastatic BC, we studied the effects of CM-1758 alone or in combination with anti-PD-L1 not only on tumor cells, but also in the tumor microenvironment. In vitro, we found that CM-1758 has cytotoxic and cytostatic effects either by inducing apoptosis or cell cycle arrest in BC cells at low micromolar levels. PD-L1 is epigenetically regulated by histone acetylation marks and is induced after treatment with CM-1758. We also observed that treatment with CM-1758 led to an important delay in tumor growth and a higher CD8 + T cell tumor infiltration. Moreover, anti-PD-L1 alone or in combination with CM-1758 reprogramed macrophage differentiation towards a M1-like polarization state and increased of pro-inflammatory cytokines systemically, yielding potential further antitumor effects. Our results suggest the possibility of combining HDAC inhibitors with immunotherapies for the management of advanced metastatic BC.

SUBMITTER: Nunes SP 

PROVIDER: S-EPMC10764810 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications


Alterations in the epigenetic machinery in both tumor and immune cells contribute to bladder cancer (BC) development, constituting a promising target as an alternative therapeutic option. Here, we have explored the effects of a novel histone deacetylase (HDAC) inhibitor CM-1758, alone or in combination with immune checkpoint inhibitors (ICI) in BC. We determined the antitumor effects of CM-1758 in various BC cell lines together with the induction of broad transcriptional changes, with focus on t  ...[more]

Similar Datasets

2024-01-04 | GSE245122 | GEO
| PRJNA1026976 | ENA
| S-EPMC8821108 | biostudies-literature
| S-EPMC5324139 | biostudies-literature
| S-EPMC8882770 | biostudies-literature
| S-EPMC11006502 | biostudies-literature
| S-EPMC6413095 | biostudies-literature
| S-EPMC6142243 | biostudies-literature
| S-EPMC8464715 | biostudies-literature
| S-EPMC9641363 | biostudies-literature